Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/06/21
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 08/05/21
Exelixis Files US Application For Expanded Use Of Cabometyx In Patients 12+ Years With Thyroid CancerBenzinga • 08/05/21
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 08/05/21
Earnings Preview: Exelixis (EXEL) Q2 Earnings Expected to DeclineZacks Investment Research • 07/29/21
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021Business Wire • 07/22/21
Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?The Motley Fool • 07/09/21
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021Business Wire • 07/08/21
Will Exelixis Stock See Even Lower Levels After Negative Data From A Clinical Trial?Forbes • 06/30/21
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver CancerBusiness Wire • 06/28/21
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary CancersZacks Investment Research • 06/15/21
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid TumorsBusiness Wire • 06/14/21
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021Business Wire • 06/07/21